HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS), maintaining an $8 price target on the stock.
April 19, 2024 | 6:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Barinthus Biotherapeutics with an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst could positively influence investor sentiment towards BRNS, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100